RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

I don't get what you're writing. Is it your impression that the private investors are demanding a say in the ADHD trial design, or that the amount of money they foresee getting will determine the trial design? If it's the latter, that sounds penny-wise, pound-foolish. At this stage in the game, trying to establish efficacy of their lead compound in what is effectively their last real chance at viability on the cheap is completely stupid.